Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abatacept

- PMLiVE

Keytruda filed for first- and second-line bladder cancer

Merck & Co hopes to gain advantage over Opdivo and Tecentriq with first-line setting

- PMLiVE

Opdivo gets FDA green light to treat bladder cancer

BMS adds new US indication to its checkpoint inhibitor

AstraZeneca AZ

2017 set to be a “defining year” for AZ

Potential immuno-oncology blockbuster durvalumab leads the charge for AZ’s new launches

Roche Basel Switzerland

Tecentriq growth offsets Avastin’s US decline at Roche

Shifts focus to newer therapies in anticipation of brewing biosimilar competition

- PMLiVE

AbbVie weak on new drug sales, but Humira stays strong

World’s biggest-selling drug has record quarter while Imbruvica and Venclexta fall short

Bristol-Myers Squibb (BMS) building

Opdivo drives growth at BMS, but US sales slow down

Sales beginning to lose momentum despite new indications bringing in $1.3bn for Q4

Novartis Gehry Building

Novartis ‘reviewing options’ for Alcon division

Possible sale or spin-off in store for eyecare unit as firm reports Q4 operating loss of $132m

- PMLiVE

Merck settles PD-1 patent lawsuit with BMS and Ono

Agrees to pay $625m settlement plus royalties on sales of Keytruda until 2026

Bristol-Myers Squibb (BMS) building

BMS won’t seek quick okay for Opdivo combo in lung cancer

No longer intends to file for accelerated approval, pushing predicted approval date back to late 2018

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

- PMLiVE

Merck pays Vertex $230m upfront for cancer programmes

Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links